Peripherally acting mu-opioid antagonists (PAMORA). PAMORAs indicated for the treatment of OIC include naloxegol, naldemedine, and methylnatrexone. These agents are opioid antagonists selective to ...

About 9-12 million Americans suffer from chronic pain annually, and most are prescribed opioid medications to treat and control their symptoms 1. While opioids can help relieve and manage chronic pain ...

Electroacupuncture increased weekly spontaneous bowel movements and improved quality of life in patients with cancer and opioid-induced constipation, according to data published in JAMA Network Open. ...

The FDA has approved the oral treatment for opioid-induced constipation naloxegol (Movantik), according to a Gastroenterology & Endoscopy News report. Movantik is designed for adults with chronic ...

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved opioid-induced constipation (OIC) compared to placebo in ...

PALM SPRINGS, California — A peripherally acting oral μ-opioid receptor antagonist is superior to placebo in treating opioid-induced constipation (OIC) and doesn't reduce the analgesic effect of ...

DEAR DR. ROACH: I’m severely constipated. My doctor has me on seven medications and supplements. I would like your opinion on taking all of them throughout the day. They are Movantik (I take Tylenol ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

At this year’s PAINWeek Conference in Las Vegas, Salix Pharmaceuticals sponsored an interactive product theater panel to discuss the challenges associated with OIC in clinical practice, how to address ...

Once OIC is diagnosed, regardless of which treatment modality is chosen, it is essential to emphasize the importance of adherence to and consistency with the treatment. Understanding the patient’s ...